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Abstract
Tumors are infiltrated by macrophages, T and B-lymphocytes, which may favor tumor development by promoting
angiogenesis, growth and invasion. The aim of this study was to investigate the clinical relevance of the relative amount of
macrophages (CD68+), T-cells (CD3+) and B-cells (CD20+) at the invasive front of breast carcinomas, and the expression of
matrix metalloproteases (MMPs) and their inhibitors (TIMPs) either at the invasive front or at the tumor center. We
performed an immunohistochemical study counting CD3, CD20 and CD68 positive cells at the invasive front, in 102 breast
carcinomas. Also, tissue sections were stained with MMP-2, -9, -11, -14 and TIMP-2 antibodies, and immunoreactivity
location, percentage of reactive area and intensity were determined at the invasive front and at the tumor center. The
results showed that an increased CD68 count and CD68/(CD3+CD20) ratio were directly associated with both MMP-11 and
TIMP-2 expression by mononuclear inflammatory cells at the tumor center (p = 0.041 and p = 0.025 for CD68 count and
p = 0.001 and p = 0.045 for ratio, respectively for MMP-11 and TIMP-2). In addition, a high CD68/(CD3+CD20) ratio (.0.05)
was directly associated with a higher probability of shortened relapse-free survival. Multivariate analysis revealed that CD68/
(CD3+CD20) ratio was an independent factor associated with distant relapse-free survival (RR: 2.54, CI: (1.23–5.24), p,0.01).
Therefore, CD68/(CD3+CD20) ratio at the invasive front could be used as an important prognostic marker.
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Introduction
Development of an invasive cancer is not only the result of
genetic changes in tumor cells but also the result of the interplay
between tumor and stromal cells [1]. Tumors are infiltrated by a
large number of immune cells that constitute the main cell
population of tumor microenvironment, where they can account
for up to 50% of the total tumor mass in invasive breast
carcinomas. Historically, tumor-infiltrating leukocytes have been
considered as an intrinsic defensive mechanism against developing
tumors [2–3]. However, increasing evidence indicates that
leukocyte infiltration may favor tumor development by promoting
angiogenesis, growth, and invasion [4–5]. This may be due to
inflammatory cells that probably influence cancer promotion by
secreting cytokines, growth factors, chemokines and proteases,
which stimulate proliferation and invasiveness of cancer cells [6–
8].
Inflammatory cells have gained a renewed interest in breast
cancer research due to our increased understanding of their role in
tumor development, and also due to our increased ability to
identify each cell type. Leukocyte infiltrate includes a variable
representation of leukocytes, including macrophages, neutrophils,
mast cells, and T and B-lymphocytes [4,9]. There are evidences
indicating that different types of breast carcinomas may have
different types of leukocyte infiltrate with distinct abilities to
control tumor growth according to their tumor dissemination.
Thus, whereas macrophages are known to have several pro-tumor
functions and macrophage infiltration has also been associated
with worse prognosis [4,10–11], it has been reported that both T-
and B-lymphocytes perform an important immunological response
by inhibiting cancer development and progression [12–20].
Metastasis development is regulated not only by intrinsic genetic
changes in malignant cells, but also by the tumor microenviron-
ment. Matrix metalloproteases (MMPs) play an essential role in
the degradation of the stromal connective tissue and basement
membrane components, which are key elements in tumor invasion
and metastasis. In fact, in the metastatic process across the axillary
lymph node chain in breast cancer, MMP-1 expression by
mononuclear inflammatory cells (MICs) from the sentinel lymph
node (SLN) was significantly associated with metastatic spread to
non-SLNs [21]. MMPs cleave proapoptotic factors and induce a
more aggressive phenotype generating apoptotic resistant cells
[22], and also regulate cancer-related angiogenesis, both positively
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through their ability to mobilize or activate proangiogenic factors
[23], or negatively through the generation of angiogenesis
inhibitors, such as angiostatin and endostatin [24]. The activity
of MMPs is specifically inhibited by the so-called tissue inhibitors
of metalloproteases (TIMPs). In previous reports we analyzed the
expression of several MMPs and TIMPs (MMP-1, 2, 7, 9, 11, 13
and 14, and TIMP-1, 2 and 3), either at the invasive front or at the
tumor center of breast carcinomas, in many of the women
included in the present study [25–28]. Thus, we identified a
phenotype of MICs characterized by the expression of specific
MMPs and TIMPs (MMP-2, 9 11 and 14, and with TIMP-2) in
the tumor center, associated with distant metastasis development
[25–26], suggesting that inflammatory cells at the invasive front
can polarize their phenotype impacting on tumor progression [27].
These tumors also showed an up-regulation of inflammatory-
related genes (IL-1, -5, -6 and -17, IFNb and NFkB), which
emphasize their importance in promoting disease metastasis and
recurrence [29].
Considering that the invasive front is the area where some of the
most important interactions between cancer cells and tumor
supporting stroma take place [30], we investigate the relevance of
the relative amount of macrophages (CD68), T-cells (CD3) and B-
Table 1. Basal characteristics of 102 patients with invasive ductal carcinoma of the breast.
CHARACTERISTICS Without recurrence No. (%) With recurrence No. (%)
Total cases 59 (100) 43 (100)
Menopausal status
Premenopausal 18 (30.5) 12 (27.9)
Postmenopausal 41 (69.5) 31 (72.1)
Tumoral size
T1 31 (52.5) 19 (44.2)
T2 28 (47.5) 24 (55.8)
Nodal status
N (2) 28 (47.5) 12 (27.9)
N (+) 31 (52.5) 31 (72.1)
Histological grade
Well Dif. (I) 20 (33.9) 7 (16.3)
Mod. Dif. (II) 31 (52.5) 16 (37.2)
Poorly Dif. (III) 8 (13.6) 20 (46.5)
Nottingham prognostic index
,3.4 25 (42.4) 8 (18.6)
3.4–5.4 25 (42.4) 22 (51.2)
.5.4 9 (15.3) 13 (30.2)
Estrogen Receptor
Negative 16 (27.1) 23 (53.5)
Positive 31 (52.5) 18 (41.9)
Progesterone Receptor
Negative 20 (33.9) 27 (62.8)
Positive 27 (45.8) 14 (32.6)
Adjuvant radiotherapy
No 44 (74.6) 21 (48.8)
Yes 15 (25.4) 22 (51.2)
Adjuvant systemic therapy
Chemotherapy 18 (30.5) 18 (41.9)
Tamoxifen 24 (40.7) 9 (20.9)
Chemotherapy plus sequential Tamoxifen 10 (16.9) 7 (16.3)
No treatment 7 (11.9) 9 (20.9)
HER2 Status
Negative 49 (83.1) 36 (83.7)
Positive 8 (13.6) 7 (16.3)
Basal like phenotype
Non basal like 30 (50.8) 23 (53.5)
Basal like 15 (25.4) 18 (41.9)
doi:10.1371/journal.pone.0052796.t001
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cells (CD20) in this tumor location from breast carcinomas. Also,
we study their relationship with MMPs and TIMPs expression,
either at the invasive front or at the tumor center. Thus, we found
that a high CD68/(CD3+CD20) ratio (.0.5) at the invasive front
is associated with tumor aggressiveness and poor prognosis in
patients.
Materials and Methods
Ethics Statement
Women were treated according to the guidelines used in our
Institution (Hospital de Jove). Written informed consent, approved
by ‘‘Hospital de Jove Ethics and Investigation Committee’’, was
obtained from all patients before the evaluation of tumor samples.
Figure 1. Representative examples of immunohistochemical stainings at the invasive front from breast carcinomas (6200
magnification). (A) Membranous staining of CD3 indicating T-lymphocytes. (B) Membranous staining of CD20 indicating B-lymphocytes. (C)
Cytoplasmic staining of CD68 indicating macrophages.
doi:10.1371/journal.pone.0052796.g001
Figure 2. Distribution of the total number of CD markers by mm2 at the invasive front, in 102 breast carcinomas. CD3 (A), CD20 (B)
and CD68 (C).
doi:10.1371/journal.pone.0052796.g002
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The study adhered to National regulations and was approved by
our Institution’s Ethics and Investigation Committee.
Patient selection, characteristics and tissue specimen
handling
This study comprises 102 women with a histological confirmed
diagnosis of early invasive breast cancer and treated between 1990
and 2003. Many of these women have been included in previous
studies of our group [25–28]. We selected women with the
following inclusion criteria: invasive ductal carcinoma and a
minimum of 5 years of follow-up for those women without tumor
recurrence. The exclusion criteria were the following: metastatic
disease at diagnosis, prior history of any kind of malignant tumor,
bilateral breast cancer at diagnosis, have been treated with any
type of neoadjuvant therapy, development of loco-regional
recurrence during the follow-up period or development of a
second primary cancer. From patients fulfilling these criteria, we
randomly selected a sample size of 102 patients in accordance to 4
different groups stratified with regard to nodal status and to the
development of metastatic disease, which were the key measure
variables of the study. Thus, we included an important number of
cases in both node-positive and node-negative patient subgroups in
order to guarantee the statistical power of the survival analysis.
Patient characteristics included in the two main groups, with or
without distant metastases, are listed in Table 1. Menopausal
status was defined as ‘‘postmenopausal’’ if 1 year was elapsed since
the last menstrual period. For reporting the Histological Grade we
used the Nottingham combined histologic grade (Elston-Ellis
modification of Scarff-Bloom-Richardson grading system) [31].
The end-point of our study was distant metastatic relapse. The
median follow-up period in patients without metastases was 85
months, and 52 months in patients with metastases.
Tissue arrays and immunohistochemistry
Breast carcinoma tissue samples were obtained at the time of
surgery. Samples were removed from the tumors, avoiding grossly
Table 2. Relationship between inflammatory cells count or ratio and clinico- pathological characteristics in 102 patients with
invasive ductal carcinoma of the breast.
CHARACTERISTICS No. CD3 CD20 CD68 CD68/(CD3+CD20)
median (range) median (range) median (range) median (range)
Total cases 102 214 (0–999) 29 (0–1152) 141 (14–727) 0.5 (0–6.6)
Menopausal status p=0.009
Premenopausal 30 322 (9–999) 50 (0–1121) 158 (31–404) 0.3 (0.1–5.4)
Postmenopausal 72 167 (0–987) 18 (0–1152) 128 (14–727) 0.5 (0–6.6)
Tumoral size
T1 50 207 (0–987) 22 (0–1152) 128 (15–727) 0.5 (0–5.4)
T2 52 242 (12–999) 34 (0–1121) 154 (14–577) 0.6 (0.1–6.6)
Nodal status
N (2) 40 201 (9–987) 27 (0–1152) 136 (15–727) 0.5 (0.1–6.3)
N (+) 62 250 (0–999) 32 (0–1121) 142 (14–577) 0.6 (0–6.6)
Histological grade
Well Dif. (I) 27 197 (9–987) 25 (0–1152) 140 (15–727) 0.5 (0.1–5.4)
Mod. Dif. (II) 47 228 (12–999) 30 (0–1121) 142 (49–577) 0.6 (0.1–6.6)
Poorly Dif. (III) 28 252 (0–542) 35 (0–156) 139 (14–416) 0.6 (0–5.4)
Nottingham prognostic index
,3.4 33 172 (9–954) 7 (0–655) 122 (15–727) 0.5 (0.1–5.4)
3.4–5.4 47 267 (0–999) 41 (0–1152) 143 (21–577) 0.5 (0–6.6)
.5.4 22 250 (14–756) 40 (0–252) 170 (14–416) 0.5 (0.1–4.0)
Estrogen Receptor p=0.040
Negative 39 298 (0–987) 41 (0–1152) 181 (14–727) 0.6 (0–4)
Positive 49 151 (9–895) 10 (0–1121) 122 (34–362) 0.6 (0.1–6.3)
Progesterone Receptor p=0.003 p=0.002
Negative 47 267 (27–987) 40 (0–1152) 182 (14–727) 0.6 (0.1–6.1)
Positive 41 144 (0–895) 10 (0–1121) 105 (35–314) 0.6 (0–6.3)
HER2 Status p=0.009 p=0.027
Negative 85 209 (0–999) 16 (0–1152) 137 (14–727) 0.5 (0–6.6)
Positive 15 359 (36–917) 101 (0–576) 186 (54–577) 0.6 (0.1–1.1)
Basal like phenotype
Non basal like 53 197 (9–895) 14 (0–1121) 137 (34–577) 0.7 (0.1–6.3)
Basal like 33 251 (0–987) 40 (0–1152) 142 (14–727) 0.4 (0–4.0)
Mann-Whithney or Kruskall-Wallis tests.
doi:10.1371/journal.pone.0052796.t002
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necrotic tissues, routinely fixed, paraffin-embedded and stored.
Histopathological representative tumor areas of invasive front and
tumor center were defined in hematoxylin and eosin-stained
sections and marked on the slide. The invasive front was defined as
the tumor advancing edge, which corresponds to a 2 mm margin
surrounding the tumor and containing cancerous cells, and the
tumor center was defined as the tumor area inside the invasive
front. Tumor tissue microarray (TMA) blocks containing primary
tumor samples were performed as described previously [25]. We
analyzed 2 cores of the invasive front and 2 cores of the tumor
center in each case (double redundancy) as it has been
demonstrated to correlate properly with conventional immuno-
histochemical staining methods [25,27].
Four composite high-density TMA blocks were performed,
consecutively cut in 5 mm sections with a microtome (Leica
Microsystems GmbH, Wetzlar, Germany) and transferred to
adhesive-coated slides. One section from each TMA block was
stained with hematoxylin and eosin, and these slides were then
reviewed to confirm that the sample was representative of the
invasive front and tumor center of the original tumor. Immuno-
histochemistry was performed using a TechMate TM50 auto-
stainer (Dako, Glostrup, Denmark), where sections were incubated
with the following antibodies (ready to use): CD3 (T-lymphocytes),
CD20 (B-lymphocytes) and CD68 (macrophages) all purchased
from Dako (Glostrup, Denmark).
In previous reports from our group, we found a specific MICs
phenotype characterized by high MMP-2, 9, 11, 14, and TIMP-2
expression, which correlated significantly with distant metastasis
development [25–28]. Consequently, in the present study we
performed a new staining set using antibodies against these specific
proteins, in the tissue arrays from the invasive front and those from
the tumor center. Antibodies for MMPs and TIMPs were
purchased from Neomarker (Lab Vision Corporation, Fremont,
CA, USA), and the dilution used was: 1/50 for MMP-2, -14 and
TIMP-2; 1/100 for MMP-9; and 1/200 for MMP-11. To enhance
antigen retrieval, tissue sections were treated in a PT-LinkH (Dako)
at 97uC for 20 min, in citrate buffer of pH 6.1 for MMP-14, in
EDTA buffer of pH 9 for TIMP-2. Antibodies for MMP-2, -9 and
-11 do not require antigen retrieval. The negative control was
DakoCytomation mouse or rabbit serum diluted at the same
concentration as the primary antibody. All the dilutions were
made in Antibody Diluent, (Dako, Glostrup, Denmark) and
incubated 30 min at room temperature.
Endogenous peroxidase activity was blocked by incubating the
slides in peroxidase-blocking solution (Dako) for 5 min. The
EnVision Detection Kit (Dako) was used as the staining detection
system. Sections were counterstained with hematoxylin, dehydrat-
ed with ethanol, and permanently coverslipped.
Immunohistochemistry analysis
Five fields per core, corresponding to areas of higher
immunostaining and without necrosis, were evaluated with a
4006 power objective, counting CD3, CD20 and CD68 positive
cells, in 1 mm2 final area, at the invasive front. If there was no
tumor sample in a particular core, 10 fields were then evaluated in
another one in order to obtain the same final area. We obtain a
total score and this is the value of CD3, CD20 or CD68 for each
tumor.
For each MMP or TIMP antibody studied, we determined the
immunoreactivity location, percentage of reactive area and
intensity, at the invasive front and at the tumor center. An image
analysis system composed of the Olympus BX51 microscope,
Figure 3. Representative example of immunostaining. MMP11 (A) and TIMP2 (B) immunostaining at the tumor center and MMP9 (C) and
MMP14 (D) at the invasive front (6200 magnification), indicating the different cell types. Tumor cells (w), lymphocytes ( ) and macrophages ( ).
doi:10.1371/journal.pone.0052796.g003
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digital camera system DP12 and soft analysis (analySISH, Soft
Imaging System, Mu¨nster, Germany) was used in the tumor
sections (stained with antibodies and counterstained with hema-
toxylin), as described before [32]. To evaluate immunostaining
intensity we used a numeric score ranging from 0 to 3, reflecting
the intensity as follows: 0, no reactivity; 1, weak reactivity; 2,
moderate reactivity; and 3, intense reactivity. Using an Excel
spreadsheet, the mean score was obtained by multiplying the
intensity score (I) by the percentage of reactivity area (PA) and the
results were added together (total score: I6PA). This overall score
was then averaged with the number of cores performed for each
patient. If there was no tumor in a particular core, then no score
was given. In addition, the mean score of two core biopsy samples
was calculated for each tumor. This scoring evaluation was based
on a global evaluation of staining areas corresponding to tumor
cells as well as to stromal cells. Nevertheless, in the present work
we also evaluated the immunohistochemical staining exclusively
for mononuclear inflammatory cells (MICs).
Statistical analysis
Differences in percentages were calculated with the chi-square
test. Immunostaining score values for each protein were expressed
as a median (range). Correlation between score values was
Figure 4. Probability of relapse-free survival as a function of CDmarkers count for 102 patients with invasive ductal carcinoma. CD3
count (A), CD20 count (B), CD68 count (C) and CD68/(CD3+CD20) ratio (D).
doi:10.1371/journal.pone.0052796.g004
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calculated by using the Spearman correlation test. Comparison of
immunostaining values between groups was made with the Mann-
Whitney or Kruskall-Wallis tests. Statistical results were corrected
applying Bonferroni’s correction. For relapse-free survival analysis
we used the Cox’s univariate method. Cox’s regression model was
used to examine interactions between different prognostic factors
in multivariate analysis. Only parameters that achieve statistical
significance for distant relapse-free survival in the univariate
analysis were included in the multivariate analysis. The PASW
Statistics 18.0 software (SPSS Inc, Chicago, IL, USA) was used for
all calculations. p,0.05 was considered as significant.
Results
Immunostainings for CD3, CD20 and CD68 were performed in
TMA blocks from invasive ductal carcinoma of the breast
(Figure 1), showing a membranous staining for CD3 and CD20,
whereas CD68 staining is found in the cytoplasm. Our results
demonstrate a wide variability among tumors in the number of
CD3+ T-cells (median: 214.00 (0–999), CD20+ B-cells (29.50 (0–
1152) or CD68+ macrophages (141.00 (14–727), by 1 mm2 at the
invasive front (Figure 2). We found direct correlations between the
number of CD68+ macrophages and the number of CD3+ T-cells
(r sub S= 0.57; p= 0.0001) or the number of CD20+ B-cells (r sub
S= 0.51; p= 0.0001), and specially between the number of CD3+
T-cells and the number of CD20+ B-cells (r sub S=0.71;
p = 0.0001).
We examined the possible relationship between the overall
number of intratumoral MICs at the invasive front, or the relative
ratio of these cells [number of CD68+ macrophages/number of
lymphocytes (number of CD3+ T-cells + number of CD20+ B-
cells), further named as CD68/(CD3+CD20) ratio], and the
clinico-pathological characteristics of patients and tumors
(Table 2). Our results demonstrated a direct relationship between
the number of CD3+ T-cells and premenopausal status (p = 0.009);
whereas this same cell count was inversely associated with both
ER+ and PgR+ status (p = 0.04 and p= 0.003, respectively). The
number of CD20+ B-cells was directly associated with HER2+
status (p = 0.009). The number of CD68+ macrophages was
inversely associated with PgR+ status and directly associated with
HER2+ status (p = 0.027). However, our results showed no
significant association between the CD68/(CD3+CD20) ratio
and any clinico-pathological characteristics (Table 2).
We had previously identified a significant percentage of tumors
with a MICs phenotype characterized by a molecular profile with
specific MMPs and TIMPs increased expression, and associated
with a high metastatic rate [25–28]. Thus, in the present work we
determined the expression of these significant proteins (MMP-2, 9,
11, 14, and TIMP-2) in the tumor samples, and analyzed the
possible relationship between the presence of different MICs
phenotypes at the invasive front, and MMPs and TIMPs
expressions by tumors both in the invasive front and in the tumor
center.
With regard to global expression (score values) of MMPs and
TIMPs, our result showed a direct correlation between MMP-2
score values and CD3 (r = 0.21, p= 0.038), CD20 (r = 0.25,
p = 0.011) or CD68 (r = 0.32, p= 0.001) counts at the invasive
front; whereas MMP-9 score values correlated with CD68 count
(r = 0.21, p = 0.041) in this same tumor location. On the other
hand, TIMP-2 score values at the tumor center correlated
inversely with CD3 (r =20.23, p= 0.021) or with CD20
(r =20.21, p= 0.036) count in the invasive front, but correlated
directly with CD68/(CD3+CD20) ratio in this same tumor
location (r = 0.24, p = 0.014).
Figure 3 shows examples of immunostaining for different MMPs
and TIMPs, at tumor center and at the invasive front. We found
several significant associations between the different MICs counts
at the invasive front and the expression of MMPs and TIMPs by
MICs from the invasive front or from the tumor center (Table 3).
Thus, high CD3, CD20 or CD68 counts were significantly
associated with MMP-9 expression, at the invasive front; whereas
high CD68 count was significantly associated with MMP-14 and
TIMP2 in this same tumor location. Also, we found that high
CD68 count and CD68/(CD3+CD20) ratio were associated with
both MMP-11 and TIMP-2 expressions by MICs at the tumor
Table 4. Cox’s univariate (HR) and multivariate (RR) analysis of the significant relationships between MMPs, TIMPs expression or
CD68/(CD3+CD20) ratio at the tumor center or at the invasive front, and relapse-free survival.
Tumor location Factor No. of patients Event frequency HR (95% CI) RR (95% CI)
TUMOR CENTER TIMP2
Score , median vs. .median 51/51 9/34 4.62 (2.21–9.65)**** 3.23 (1.51–6.92)***
MIC (2) vs. (+) 72/30 20/23 3.77 (2.06–6.89)**** 4.37 (2.31–8.25)****
MMP11
MIC (2) vs. (+) 76/26 18/25 9.19 (4.73–17.85)**** 8.80 (4.40–17.61)****
INVASIVE FRONT MMP9
Score , median vs. .median 50/49 16/25 2.03 (1.08–3.80)* 2.22 (1.15–4.29)*
MMP14
MIC (2) vs. (+) 74/24 24/17 3.38 (1.81–6.31)**** 3.41 (1.75–6.63)****
TIMP2
MIC (2) vs. (+) 49/50 15/26 1.89 (1.01–3.58)* 2.51 (1.28–4.92)**
CD68/(CD3+CD20) Ratio 51/50 13/29 2.68 (1.39–5.17)*** 2.54 (1.23–5.24)**
Abbreviations: MIC: mononuclear inflammatory cells; HR: hazard ratio; RR: relative risk; CI: confidence interval.
*p,0.05;
**p,0.01;
***p,0.005;
****p,0.001.
doi:10.1371/journal.pone.0052796.t004
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center. In addition, it is interesting our finding indicating that if
there is a high CD68/(CD3+CD20) ratio at the invasive front,
most of MICs with a positive MMP-11 or TIMP-2 phenotype at
the tumor center are macrophages (Figure 3A and B, respectively).
In this figure, MMP-11 staining demonstrates that apart from
tumor cells with large nucleus and an intense cytoplasmic staining,
there are a small number of lymphocytes with rounded nucleus
surrounded by a small positive cytoplasm, but the most abundant
cells type in the tumor center are macrophages, which are the
large, round cells that contain a central round nucleus and an
abundant clear positive cytoplasm.
The possible influence of the number of the different
inflammatory cell types on relapse-free survival was evaluated in
all patients included in the present study. For this purpose, we took
the corresponding median value of the total number of each cell
type by 1 mm2 at the invasive front as cut-off point. Univariate
analysis indicates that CD3, CD20, or CD68 count showed no
significant associations with relapse-free survival (Figure 4).
Nevertheless, our results showed that a high CD68/(CD3+CD20)
ratio was significantly associated with a higher probability of
shortened relapse-free survival (p = 0.002) (Table 4 and Figure 4D).
Multivariate analysis according to Cox’s model demonstrated that
tumor stage (II: (relative risk (RR) (confidence interval
(CI) = 1.8(0.7–4.5); III: 4.6(1.8–12.0); p=0.003) and PgR status
(positive: 0.4(0.2–0.8), p=0.011) were significant and indepen-
dently associated with distant relapse-free survival. Nevertheless,
this same analysis also demonstrated that CD68/(CD3+CD20)
ratio was significant and independently associated with distant
relapse-free survival (Table 4).
Discussion
Inflammation is now considered a hallmark of cancer and can
play a role in all aspects of tumor biology, including initiation,
promotion, angiogenesis, and metastasis [4,27,33–34]. It is known
that the activation of oncogenes can trigger the production of
inflammatory molecules and the recruitment of inflammatory cells.
But the potential effects of the inflammatory cell infiltrate in breast
cancer seem to be diverse and complex. Therefore, in this study
we investigate the impact of different inflammatory cell types at
the invasive front from breast carcinomas on distant metastasis
development. We consider that this is of special interest because
the invasive front is the area where some of the most important
interactions between cancer cells and the tumor supporting stroma
take place [30]. Our results showed a biological heterogeneity
among breast tumors with regard to these cellular infiltrates at the
invasive front. In addition, we found that a high CD68/
(CD3+CD20) ratio at the invasive front is significant and
independently associated with the occurrence of distant metastasis.
There are data indicating that, depending on the cell type
present and their functional profile, inflammatory cells can either
suppress or promote tumor growth. We analyzed the expression
profile of the individual inflammatory cell types, and our results
are in accordance with other studies indicating that tumor-
infiltrating lymphocytes correlate with hormone receptor-negative
or HER2+ status, or with high grade/highly proliferative tumors,
although we did not find correlation with favorable long-term
prognosis [12–19]. In addition, it has been reported that activated
B cells can mediate tumor regression by itself and confers host T-
cell antitumor immunity. Likewise, it was suggested that effector B
cells can serve as a useful adjunct in adoptive T-cell therapy [35].
Tumor-associated macrophages arise from circulating mono-
cytes that migrate into tissues in response to chemical signals and
differentiate into macrophages. In breast cancer, macrophages
have been found to comprise up to 50% of the breast tumor mass
[36]. Tumor-associated macrophages produce a variety of
cytokines and chemokines, as well as growth factors for both
epithelial and endothelial cells, which play a key role in tumor
growth and metastasis [4,10–11]. Our results are in accordance
with previous studies reporting an association between macro-
phages density and PgR2 or HER-2+ status [37]. However, also in
accordance with Mahmoud et al., we found that overall
macrophage numbers are not related to prognosis in breast
cancer in a multivariate analysis [37]. This may be due the density
of macrophages was correlated with higher tumor grade in the
present study as well as in previous studies [37–39]. Hence,
multivariate analysis is thus essential when examining the relation
between macrophage infiltration and survival. Nevertheless, this
latter analysis led us to identify a high CD68/(CD3+CD20) ratio
was a potent independent factor for predicting distant metastasis
relapse-free survival in our patient population. Therefore, we
describe here, for the first time, a study evaluating the relative
amount of different MICs at the invasive front in breast
carcinomas, using a new ratio that correlates with patient survival
and could be useful in predicting patient outcome. We consider
this is a relevant finding since the role of inflammatory cells in
cancer seems to be complex, and this ratio can reflect a more
objective result of the interactions between both anti-tumor and
pro-tumor effects of the different inflammatory cells.
The end point of the present study was the occurrence of distant
metastasis, which is regulated not only by intrinsic genetic changes
in malignant cells, but also by the microenvironment. MMPs play
an essential role in tumor invasion and metastasis via degradation
of the stromal connective tissue and basement membrane
components, and are inhibited by TIMPs. In previous reports
we identify a phenotype of MICs characterized by the expression
of specific MMPs and TIMPs at the tumor center, and associated
with distant metastasis development [25–28], which also showed
an up-regulation of inflammatory-related genes [29]. According to
this, in the present study we determined the expression of these
significant proteins (MMP-2, 9, 11, 14, and TIMP-2) in those
breast cancer samples and analyzed the possible relationship
between the different inflammatory cells counts at the invasive
front and the expression of MMPs and TIMPs, either at the
invasive front or at the tumor center. Then, we found several
associations between the inflammatory cell types and some of these
factors. Nevertheless, the most relevant finding was the association
between high CD68/(CD3+CD20) ratio and the expression of
MMP-11 (stromalysin-3) or TIMP-2 by the MICs at the tumor
center. This is a relevant finding considering that both MMP-11
and TIMP-2 are the two principal factors defining the pro-
metastatic phenotype of MICs in our previous studies [25–28].
Therefore, these results may indicate that a high CD68/
(CD3+CD20) ratio at the invasive front contributes to polarize
macrophages to achieve a high metastatic phenotype at the tumor
center. In addition, it is remarkable our finding indicating that if
there is a high CD68/(CD3+CD20) ratio at the invasive front,
most of MICs with a positive MMP-11 or TIMP-2 phenotype at
the tumor center are macrophages.
A limitation of the present study was the lack of a complete
study of the count for the different MICs at the tumor center. It
was due to the absence of enough tissue sample in many cases,
because of their utilization in our previous expression studies on
MMPs, TIMPs and other factors in breast carcinomas. Neverthe-
less, we observed that most of MICs in tumor center have
macrophage-like morphology, indicating an important contribu-
tion of these stromal cells to tumor biology in this tumor location.
Inflammatory Cells Ratio in Metastasis Development
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e52796
In summary, our results contribute to characterize the
inflammatory cell infiltrate in breast cancer, and their relationship
with prognostic evaluation and MMPs/TIMPs expression. Further
studies will be necessary to assess if this CD68/(CD3+CD20) ratio
at the invasive front can contribute to identify patients with breast
cancer candidates to different therapeutic strategies based on
immuno-modulation. In fact, several strategies against tumor-
associated macrophages have already been published [40–42], and
several reports indicate the effectiveness of activated B-cells in
cellular immunotherapy of malignancies [43–46]. Hence, to
design breast tumor immunotherapy and vaccine strategies
hereafter, it will be necessary to consider humoral immunity in
addition to the cell mediated immunity, as a potential therapeutic
tool.
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